429 related articles for article (PubMed ID: 29071527)
1. (Immuno)proteasomes as therapeutic target in acute leukemia.
Cloos J; Roeten MS; Franke NE; van Meerloo J; Zweegman S; Kaspers GJ; Jansen G
Cancer Metastasis Rev; 2017 Dec; 36(4):599-615. PubMed ID: 29071527
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
3. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
4. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
[TBL] [Abstract][Full Text] [Related]
6. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
7. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors in acute leukemia.
Niewerth D; Dingjan I; Cloos J; Jansen G; Kaspers G
Expert Rev Anticancer Ther; 2013 Mar; 13(3):327-37. PubMed ID: 23477519
[TBL] [Abstract][Full Text] [Related]
9. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
11. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
[TBL] [Abstract][Full Text] [Related]
12. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
[TBL] [Abstract][Full Text] [Related]
13. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
15. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
16. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
17. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
18. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Yang Y; Gao Y; Huang J; Yang Z; Luo H; Wang F; Xu J; Cui Y; Ding H; Lin Z; Zhai X; Qu Y; Zhang L; Liu T; Ye L; Niu T; Zheng Y
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040812
[TBL] [Abstract][Full Text] [Related]
19. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
20. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
